In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes

Ann Intern Med. 2022 May;175(5):JC54. doi: 10.7326/J22-0029. Epub 2022 May 3.

Abstract

Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-84. 35023547.

Publication types

  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Kidney
  • Naphthyridines / adverse effects
  • Renal Insufficiency, Chronic* / complications
  • Renal Insufficiency, Chronic* / drug therapy

Substances

  • Naphthyridines
  • finerenone